Korea Needs ‘More Unified’ Bio-Health Care Policy: Experts
This article was originally published in PharmAsia News
At a recent seminar in Seoul, South Korean biotechnology and health care experts positively assessed the government's ongoing efforts to nurture the sector, but called for more unified policies and clearer objectives going forward.
You may also be interested in...
Amid the recent ousting of President Park Geun-hye amid corruption allegations and a new presidential election only weeks away, the South Korean pharma industry is quickening its calls for policy support from the next administration by recommending a variety of changes.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.